CLOPIDOGREL VERSUS TICAGRELOR AND PRASUGREL IN PRIMARY PERCUTANEOUS CORONARY INTERVENTION PATIENTS WITH A NORMAL FUNCTION CYP2C19 GENE: A SUB-STUDY FROM THE POPULAR GENETICS

Daniel Claassens,Thomas Bergmeijer,Gerrit J. A. Vos,Rik S. Hermanides, Arnoud Hof,Pim van der Harst,Emanuele Barbato,Carmine Morisco,Richard M. Tjon Joe Gin,Folkert Asselbergs,Arend Mosterd,Jean-Paul Herrman,Willem J. M. Dewilde,Vera H. M. Deneer,Jurrien M. Ten Berg

Journal of the American College of Cardiology（2020）

引用 0|浏览64

暂无评分

摘要

The POPular Genetics trial demonstrated that a genotype-guided strategy benefits patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) compared to standard treatment with ticagrelor or prasugrel by reducing bleedings, without increasing

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要